Literature DB >> 35531322

Determination of unbound piperaquine in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry.

Liusheng Huang1, Vong Sok1, Usman Aslam-Mir1, Florence Marzan1, Meghan Whalen1, Philip J Rosenthal2, Francesca Aweeka1.   

Abstract

Piperaquine (PQ) is an antimalarial drug that is highly protein-bound. Variation in plasma protein contents may affect the pharmacokinetic (PK) exposure of unbound drug, leading to alteration of clinical outcomes. All published methods for determination of PQ in human plasma measure the total PQ including both bound and unbound PQ to plasma proteins. There is no published method for unbound PQ determination. Here we report an ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for determination of PQ in human plasma filtrate prepared by filtering human plasma through Millipore Microcon® centrifugal filters (10k NMWL). The filter cup had to be treated with 5% benzalkonium chloride to reduce non-specific binding to the filter devices before filtration of plasma samples. Multiple reactions monitoring (MRM) of the ion pairs m/z 535/288 for PQ and m/z 541/294 for the internal standard (IS) was selected for quantification. When electrospray ionization (ESI+) was used, paradoxical matrix effect was observed despite the structure similarity of the deuterated IS: Ion suppression for PQ versus ion enhancement for the PQ-d6, even though they were closely eluted: 0.62 min versus 0.61 min. Separation was achieved on Evo C18 column (50 × 2.1 mm, 1.7 μm, Phenomenex Inc.) eluted with 10 mM NH4OH and MeCN. When atmospheric pressure chemical ionization in positive mode (APCI+) was used for ion source, matrix effect diminished. Separation was achieved on a PFP column (30 × 2.1 mm, 1.7 μm, Waters, Corp.) eluted with aqueous 20 mM ammonium formate 0.14% trifluoroacetic acid (A) and methanol-acetonitrile (4:1, v/v) containing 0.1% trifluoroacetic acid (B) at 0.8 mL/min flow rate in a gradient mode: 30-30-80-80-30-30%B (0-0.1-1.0-1.40-1.41-1.50 min). The retention time was 0.67 min for both PQ and the IS. The method was validated with a linear calibration range from 20 to 5,000 pg/mL and applied to clinical samples.

Entities:  

Keywords:  Piperaquine; Plasma; Plasma filtrate; UHPLC-MS/MS; Unbound; free

Year:  2022        PMID: 35531322      PMCID: PMC9068709          DOI: 10.1016/j.jcoa.2022.100042

Source DB:  PubMed          Journal:  J Chromatogr Open        ISSN: 2772-3917


  18 in total

Review 1.  Drug-protein binding: a critical review of analytical tools.

Authors:  Karine Vuignier; Julie Schappler; Jean-Luc Veuthey; Pierre-Alain Carrupt; Sophie Martel
Journal:  Anal Bioanal Chem       Date:  2010-05-09       Impact factor: 4.142

Review 2.  Piperaquine: a resurgent antimalarial drug.

Authors:  Timothy M E Davis; Te-Yu Hung; Ing-Kye Sim; Harin A Karunajeewa; Kenneth F Ilett
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Reduced Exposure to Piperaquine, Compared to Adults, in Young Children Receiving Dihydroartemisinin-Piperaquine as Malaria Chemoprevention.

Authors:  Meghan E Whalen; Richard Kajubi; Nona Chamankhah; Liusheng Huang; Francis Orukan; Erika Wallender; Moses R Kamya; Grant Dorsey; Prasanna Jagannathan; Philip J Rosenthal; Norah Mwebaza; Francesca T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2019-07-22       Impact factor: 6.875

4.  Development of a Simple and Rapid Method to Measure Free Fraction of Valproic Acid in Plasma Using Ultrafiltration and Ultra High Performance Liquid Chromatography-Mass Spectroscopy: Application to Therapeutic Drug Monitoring.

Authors:  Shansen Xu; Yanan Chen; Mingming Zhao; Limei Zhao
Journal:  Ther Drug Monit       Date:  2017-10       Impact factor: 3.681

Review 5.  Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines.

Authors:  Sílvia M Illamola; Déborah Hirt; Jean M Tréluyer; Saik Urien; Sihem Benaboud
Journal:  Drug Discov Today       Date:  2014-11-20       Impact factor: 7.851

6.  Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention.

Authors:  R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka
Journal:  Clin Pharmacol Ther       Date:  2017-05-30       Impact factor: 6.875

7.  Measuring unbound versus total vancomycin concentrations in serum and plasma: methodological issues and relevance.

Authors:  Veronique Stove; Louise Coene; Mieke Carlier; Jan J De Waele; Tom Fiers; Alain G Verstraete
Journal:  Ther Drug Monit       Date:  2015-04       Impact factor: 3.681

8.  Determination of free vancomycin, ceftriaxone, cefazolin and ertapenem in plasma by ultrafiltration: impact of experimental conditions.

Authors:  Alexander Kratzer; Uwe Liebchen; Michael Schleibinger; Martin G Kees; Frieder Kees
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-05-17       Impact factor: 3.205

9.  Simultaneous determination of piperaquine and its N-oxidated metabolite in rat plasma using LC-MS/MS.

Authors:  Huixiang Liu; Meitong Zang; Aijuan Yang; Jianbo Ji; Jie Xing
Journal:  Biomed Chromatogr       Date:  2017-04-19       Impact factor: 1.902

10.  Simultaneous determination of fludarabine and clofarabine in human plasma by LC-MS/MS.

Authors:  Liusheng Huang; Patricia Lizak; Christopher C Dvorak; Francesca Aweeka; Janel Long-Boyle
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2014-05-02       Impact factor: 3.205

View more
  1 in total

1.  Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate.

Authors:  Jiahong Xiang; Mengqi Wu; Jianchao Wang; Mengmeng Lin; Mengmeng Sun; Xin Li; Ruijuan Xing; Ran Guo; Jianmin Gu; Tao Lyu; Lei Wang; Xiaowei Shi
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.